CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2015--
AVEO Oncology (NASDAQ:AVEO) today announced that management will host a
conference call and webcast on Friday, March 6, 2015, at 8:00 a.m.
Eastern Time to discuss the presentation of final results and a
predefined biomarker analysis of its BATON-CRC study, a randomized Phase
2 clinical trial of modified FOLFOX6 combined with tivozanib or
bevacizumab in metastatic colorectal cancer. The presentation, titled
“Neuropilin-1 as a potential biomarker of progression-free survival
benefit for tivozanib + mFOLFOX6 versus bevacizumab + mFOLFOX6 in
metastatic colorectal cancer: post-hoc biomarker analysis of BATON-CRC
Phase 2 trial,” will be presented in a poster session on March 6 at the
American Association for Cancer Research (AACR) Tumor Angiogenesis and
Vascular Normalization Conference in Orlando, FL.
The call can be accessed by dialing 1-877-280-4954 (domestic) or
1-857-244-7311 (international) five minutes prior to the start of the
call and providing the passcode 38640881. A replay of the call will be
available two hours after the completion of the call and can be accessed
by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international),
providing the passcode 54500453. The replay will be available for two
weeks from the date of the live call.
The live webcast of the conference call can be accessed by visiting the
investors section of the AVEO website at www.aveooncology.com.
A replay of the webcast will be archived on the AVEO website for two
weeks following the call.
A copy of the poster presentation will be made available on AVEO’s
website at www.aveooncology.com.
AVEO Oncology (NASDAQ:AVEO) is a biopharmaceutical company committed to
developing targeted therapies through biomarker-driven insights to
provide improvements in patient outcomes where significant unmet medical
needs exist. AVEO’s proprietary Human Response Platform™ has delivered
unique insights into cancer and related disease biology that are being
leveraged in the clinical development strategy of its therapeutic
candidates. For more information, please visit the company’s website at www.aveooncology.com.
Source: AVEO Oncology
Company, Media and Investor Contact: